clinicaltrials
Latest
Injectable male contraceptive tested successfully on monkeys
It's 2017, and male birth control methods haven't really advanced beyond the vasectomy -- a procedure that's been performed since the 1800s -- or condoms. That's what makes Vasalgel so intriguing. It's a "potentially" reversible method that uses gel to chemically incapacitate sperm as they pass through the vas deferens. It doesn't stop sperm production, and, like with a vasectomy, the swimmers are just absorbed into the body. In a recent experiment, male rhesus monkeys given the treatment didn't sire any offspring during a year-long study.
DEA approves MDMA study for the terminally ill
MDMA is widely used both on and off festival grounds. But the drug is quietly making a comeback as a therapeutic aid. Last week, the DEA approved a clinical trial that will use a combination of the psychedelic drug and psychotherapy to treat anxiety associated with terminal illnesses. Multidisciplinary Association for Psychedelic Studies (MAPS) has initiated the study as part of their on-going efforts to validate the effectiveness of MDMA in a scientific setting. This isn't the first time it's been used to assist psychotherapy. But if the study is successful, it will introduce a new use for the drug.
MIT duo successfully tests wireless drug-delivery microchips, more consistent than injections
Despise those daily injections of essential medication? Well folks, relief could be on the way. Over a decade ago, two MIT professors, Robert Langer and Michael Cima, first considered developing a drug-delivery microchip that could be wirelessly controlled. This past week, researchers in Cambridge -- alongside scientists from MicroCHIPS, Inc. -- announced that they have successfully used the aforementioned chip to give osteoporosis patients their daily allotment of teriparatide. "You can do remote control delivery, you can do pulsatile drug delivery, and you can deliver multiple drugs," Langer noted. Chips used in this particular study housed 20 doses each and results indicated that the delivery showed less variation than administered injections. In theory, microchips like these could be used alongside sensors that monitor glucose levels -- creating tech that could adapt to changes in a patient's condition. More info on the trial awaits in the source link below.[Thanks, Lydia]
Breast cancer vaccine proves successful in tests on mice, moves on to human subjects
Here's a cause for optimism, albeit the cautious kind. Researchers at the Cleveland Clinic Lerner Research Institute have managed to isolate a human protein that plays part in the development of breast cancer, and have produced a vaccine against its creation that has delivered an impressive success rate in testing on mice. In a test group of genetically cancer-prone rodents, none of those injected with á-lactalbumin developed the potentially deadly disease. The progress of this drug trial to testing on humans has been met with reservation by cancer research groups, who remind us that we're years away from knowing if it will actually work on our species. Still, this is quite the little breakthrough and we hope all goes according to plan.
Subretinal implant successfully tested on humans, makes blind narrowly see
How many scientists does it take to properly install a lightbulb? When that lightbulb is an implant that stimulates retinal photoreceptors to restore one's sight, quite a few -- even if they disagree whether said implant should be placed on top of the retina (requiring glasses to supply power and video feed) or underneath, using photocells to channel natural sunlight. Now, a German firm dubbed Retina Implant has scored a big win for the subretinal solution with a three-millimeter, 1,500 pixel microchip that gives patients a 12 degree field of view. Conducting human trials with 11 patients suffering from retinitis pigmentosa, the company successfully performed operations on seven, with one even managing to distinguish between similar objects (knife, fork, spoon) and perform very basic reading. Though usual disclaimers apply -- the tech is still a long way off, it only works on folks who've slowly lost their vision, etc. -- this seems like a step in the right direction, and at least one man now knows which direction that is.
